Page 2 - Pascal Prigent News Today

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placeboElafibranor was well tolerated with a safety profile

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal... | May 31, 2023

Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and...

Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as... | May 31, 2023

/PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has...

Cash, cash equivalents and current financial assets totaled €140.2 million1 as of December 31, 2022, expected to fund operations through third quarter 2024Transformative milestone expected towards end

Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet...

Genfit has signed an exclusivity agreement for the acquisition of clinical-stage biotechnology firm, Versantis, for $109m (Sfr105m).

GENFIT is set to acquire Versantis, a Swiss biotechnology company focused on addressing the growing unmet medical needs in liver diseases.

Liver disease remains the focus of Genfit, despite a high-profile clinical trial failure in the fatty liver disease NASH. The company is building out its pipeline by acquiring Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a deadly chronic liver disease complication that has no FDA-approved therapies.